313 related articles for article (PubMed ID: 26855777)
1. N-acetylcysteine in COPD: why, how, and when?
Sanguinetti CM
Multidiscip Respir Med; 2015; 11():8. PubMed ID: 26855777
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
[TBL] [Abstract][Full Text] [Related]
3. Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD.
Cazzola M; Page CP; Wedzicha JA; Celli BR; Anzueto A; Matera MG
Respir Res; 2023 Jul; 24(1):194. PubMed ID: 37517999
[TBL] [Abstract][Full Text] [Related]
4. Oxidation pathway and exacerbations in COPD: the role of NAC.
Matera MG; Calzetta L; Cazzola M
Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
[TBL] [Abstract][Full Text] [Related]
5. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
7. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
8. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients.
De Backer J; Vos W; Van Holsbeke C; Vinchurkar S; Claes R; Parizel PM; De Backer W
Int J Chron Obstruct Pulmon Dis; 2013; 8():569-79. PubMed ID: 24293993
[TBL] [Abstract][Full Text] [Related]
9. Antioxidant supplementation for lung disease in cystic fibrosis.
Ciofu O; Smith S; Lykkesfeldt J
Cochrane Database Syst Rev; 2019 Oct; 10(10):CD007020. PubMed ID: 31580490
[TBL] [Abstract][Full Text] [Related]
10. High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I-II): study protocol for a multicenter, double-blinded, parallel-group, randomized controlled trial in China.
Tian H; Zhou Y; Tang L; Wu F; Deng Z; Lin B; Huang P; Wei S; Zhao D; Zheng J; Zhong N; Ran P
Trials; 2020 Sep; 21(1):780. PubMed ID: 32917271
[TBL] [Abstract][Full Text] [Related]
11. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
12. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review.
Sadowska AM; Manuel-Y-Keenoy B; De Backer WA
Pulm Pharmacol Ther; 2007; 20(1):9-22. PubMed ID: 16458553
[TBL] [Abstract][Full Text] [Related]
13. Role of oxidative stress in the pathogenesis of COPD.
Nucera F; Mumby S; Paudel KR; Dharwal V; DI Stefano A; Casolaro V; Hansbro PM; Adcock IM; Caramori G
Minerva Med; 2022 Jun; 113(3):370-404. PubMed ID: 35142479
[TBL] [Abstract][Full Text] [Related]
14. [Oxidative stress in bronchopulmonary disease: contribution of N-acetylcysteine (NAC)].
Guerin JC; Leophonte P; Lebas FX; Liard F; Terrioux P; Boulanger P
Rev Pneumol Clin; 2005 Feb; 61(1 Pt 1):16-21. PubMed ID: 15772575
[TBL] [Abstract][Full Text] [Related]
15. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Shen Y; Cai W; Lei S; Zhang Z
COPD; 2014 Jun; 11(3):351-8. PubMed ID: 24378052
[TBL] [Abstract][Full Text] [Related]
16. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study.
Papi A; Zheng J; Criner GJ; Fabbri LM; Calverley PMA
Respir Med; 2019 Feb; 147():37-43. PubMed ID: 30704697
[TBL] [Abstract][Full Text] [Related]
17. Antioxidant therapeutic targets in COPD.
Rahman I; Kilty I
Curr Drug Targets; 2006 Jun; 7(6):707-20. PubMed ID: 16787173
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine Attenuates Cigarette Smoke-induced Alveolar Epithelial Cell Apoptosis through Reactive Oxygen Species Depletion and Glutathione Replenish In vivo and In vitro.
Zhao J; Han M; Tian Y; Zhao P; Liu X; Dong H; Feng S; Li J
Curr Pharm Biotechnol; 2023 Oct; ():. PubMed ID: 37921125
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
20. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue.
Bridgeman MM; Marsden M; Selby C; Morrison D; MacNee W
Thorax; 1994 Jul; 49(7):670-5. PubMed ID: 8066561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]